Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
2.

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Mateo J, Heymach JV, Zurita AJ.

Mol Diagn Ther. 2012 Jun 1;16(3):151-61. doi: 10.2165/11632590-000000000-00000. Review.

3.

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.

Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Review.

PMID:
22923165
4.

Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.

Naraev BG, Strosberg JR, Halfdanarson TR.

Oncology. 2012;83(3):117-27. doi: 10.1159/000339539. Epub 2012 Jul 12. Review.

5.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
6.

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

Yim KL.

Endocrine. 2011 Oct;40(2):181-6. doi: 10.1007/s12020-011-9513-y. Epub 2011 Aug 26. Review.

PMID:
21870172
7.

Medical treatment of neuroendocrine tumours.

Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):27-31. doi: 10.1097/MED.0b013e32835c034f. Review.

PMID:
23221494
8.

Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.

Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.

Anticancer Agents Med Chem. 2013 Mar;13(3):382-8. Review.

PMID:
23092266
9.

Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.

Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Epub 2012 Aug 8. Review.

PMID:
22873789
10.

Targeted agents in treatment of neuroendocrine tumors of pancreas.

Karampelas IN, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. Review.

11.

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Reidy-Lagunes D, Thornton R.

Curr Oncol Rep. 2012 Jun;14(3):249-56. doi: 10.1007/s11912-012-0232-1. Review.

PMID:
22434313
12.

Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.

Khagi S, Saif MW.

Curr Opin Oncol. 2015 Jan;27(1):38-43. doi: 10.1097/CCO.0000000000000146. Review.

PMID:
25390554
13.

Advances in the treatment of pancreatic neuroendocrine tumours.

Gao F, Visvardis EE, Sita-Lumsden A, Waxman J.

QJM. 2012 Sep;105(9):819-22. doi: 10.1093/qjmed/hcs032. Epub 2012 Feb 29. Review.

PMID:
22383691
14.

New strategies for advanced neuroendocrine tumors in the era of targeted therapy.

Dong M, Phan AT, Yao JC.

Clin Cancer Res. 2012 Apr 1;18(7):1830-6. doi: 10.1158/1078-0432.CCR-11-2105. Epub 2012 Feb 15. Review.

15.

A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.

Capdevila J, Tabernero J.

Cancer Discov. 2011 Aug;1(3):213-21. doi: 10.1158/2159-8290.CD-11-0151. Review.

16.

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.

Wolin EM.

Cancer Lett. 2013 Jul 10;335(1):1-8. doi: 10.1016/j.canlet.2013.02.016. Epub 2013 Feb 16. Review.

PMID:
23419523
17.

Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN.

J Natl Cancer Inst. 2013 Jul 17;105(14):1005-17. doi: 10.1093/jnci/djt135. Epub 2013 Jul 9. Review.

PMID:
23840053
18.

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G.

Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S91-102. doi: 10.1517/14728222.2012.665880. Epub 2012 Feb 29. Review.

PMID:
22372544
19.

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F.

Cancer Res. 2013 Mar 1;73(5):1449-53. doi: 10.1158/0008-5472.CAN-12-3923. Epub 2013 Feb 22. Review.

20.

Targeting the mTOR signaling pathway in neuroendocrine tumors.

Chan J, Kulke M.

Curr Treat Options Oncol. 2014 Sep;15(3):365-79. doi: 10.1007/s11864-014-0294-4. Review.

Supplemental Content

Support Center